377 related articles for article (PubMed ID: 25564602)
21. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
Berger ML; Eck S; Ruberg SJ
J Clin Oncol; 2010 Jul; 28(20):e343-4; author reply e345. PubMed ID: 20458030
[No Abstract] [Full Text] [Related]
22. Cancer chemotherapy: a rapidly moving train.
Shader RI
Clin Ther; 2013 Sep; 35(9):1253-4. PubMed ID: 24054701
[No Abstract] [Full Text] [Related]
23. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
24. Oncology drugs enter the US market faster than in Europe but cost more.
Mitka M
JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
[No Abstract] [Full Text] [Related]
25. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
Kwon S
Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
27. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
28. Oncologic Drugs Advisory Committee and conflicts of interest.
Burki TK
Lancet Oncol; 2016 Mar; 17(3):e95. PubMed ID: 26877161
[No Abstract] [Full Text] [Related]
29. Cancer drugs in the United States: Justum Pretium--the just price.
Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
[No Abstract] [Full Text] [Related]
30. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
31. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
32. Stocks' study renews concerns over insider trading on oncology drugs.
Goozner M
J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626
[No Abstract] [Full Text] [Related]
33. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
34. What drives diffusion of new cancer therapies?
Schmidt C
J Natl Cancer Inst; 2015 Jun; 107(6):djv162. PubMed ID: 26032609
[No Abstract] [Full Text] [Related]
35. Approval may embolden industry to combine cancer therapies.
Deng B
Nat Med; 2015 Feb; 21(2):105. PubMed ID: 25654594
[No Abstract] [Full Text] [Related]
36. Use and coverage of novel cancer agents in managed care.
Bailes JS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
[TBL] [Abstract][Full Text] [Related]
37. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
Gordon N; Stemmer SM; Greenberg D; Goldstein DA
J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
[TBL] [Abstract][Full Text] [Related]
38. [Cost/benefit analysis of cancer drugs].
Jordan B
Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
[TBL] [Abstract][Full Text] [Related]
39. Obtaining financial support for patients receiving off-label drugs.
Clancey JK; Card IC
Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389
[No Abstract] [Full Text] [Related]
40. Sticker shock sharpens focus on biologics.
McNeil C
J Natl Cancer Inst; 2007 Jun; 99(12):910-2, 914. PubMed ID: 17565148
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
